More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.78B
EPS
0.2
P/E ratio
84.5
Price to sales
4.17
Dividend yield
--
Beta
1.819653
Previous close
$16.90
Today's open
$16.92
Day's range
$16.72 - $16.98
52 week range
$9.53 - $17.78
show more
CEO
Michael B. Petras
Employees
3000
Headquarters
Broadview Heights, OH
Exchange
Nasdaq Global Select
Shares outstanding
284093929
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Sotera Health Announces Secondary Offering of Common Stock
CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.
GlobeNewsWire • Nov 6, 2025

Sotera Health Company (SHC) Q3 2025 Earnings Call Transcript
Sotera Health Company ( SHC ) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division David Windley - Jefferies LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Jason Bednar - Piper Sandler & Co., Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Good morning, and welcome to the Sotera Health Third Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
Seeking Alpha • Nov 4, 2025

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Q3 2025 net revenues increased 9.1% to $311 million , or 8.0% on a constant currency basis ( 1) , compared to Q3 2024 Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024 Q3 2025 Adjusted EBITDA ( 1 ) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024 Q3 2025 Adjusted EPS ( 1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024 Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2025. Third-quarter 2025 net revenues increased 9.1% to $311 million, compared to $285 million in the third-quarter 2024.
GlobeNewsWire • Nov 4, 2025

Here's What Key Metrics Tell Us About Sotera Health (SHC) Q3 Earnings
The headline numbers for Sotera Health (SHC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 4, 2025

Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates
Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.
Zacks Investment Research • Nov 4, 2025

Sotera Health Announces Third-Quarter 2025 Earnings Release Date
CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m.
GlobeNewsWire • Oct 21, 2025

Should You Buy Sotera Health Company (SHC) After Golden Cross?
Sotera Health Company (SHC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SHC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Zacks Investment Research • Aug 27, 2025

Sotera Health (SHC) Q2 Revenue Up 6%
Sotera Health (SHC) Q2 Revenue Up 6%
The Motley Fool • Aug 8, 2025

Sotera Health (SHC) Q2 2025 Earnings Transcript
Image source: The Motley Fool.
The Motley Fool • Aug 8, 2025

Sotera Health Company (SHC) Q2 2025 Earnings Call Transcript
Sotera Health Company (NASDAQ:SHC ) Q2 2025 Earnings Conference Call August 8, 2025 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Jonathan M. Lyons - Senior VP & CFO Michael B.
Seeking Alpha • Aug 8, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Sotera Health Company commission-free¹. Build wealth for the long term using automated trading and transfers.